Use of gliptins reduces levels of SDF-1/CXCL12 in bullous pemphigoid and type 2 diabetes, but does not increase autoantibodies against BP180 in diabetic patients

The use of dipeptidyl peptidase 4 (DPP4) inhibitors, (also known as gliptins), is associated with an increased risk of bullous pemphigoid (BP), an autoimmune blistering skin disease. To explore the mechanism behind gliptin-associated BP we investigated circulating autoantibodies against the major BP...

Descripción completa

Detalles Bibliográficos
Autores principales: Nätynki, Antti, Leisti, Päivi, Tuusa, Jussi, Varpuluoma, Outi, Huilaja, Laura, Izumi, Kentaro, Herukka, Sanna-Kaisa, Ukkola, Olavi, Junttila, Juhani, Kokkonen, Nina, Tasanen, Kaisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357937/
https://www.ncbi.nlm.nih.gov/pubmed/35958564
http://dx.doi.org/10.3389/fimmu.2022.942131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357937/
https://www.ncbi.nlm.nih.gov/pubmed/35958564
http://dx.doi.org/10.3389/fimmu.2022.942131

Ejemplares similares